A new whitepaper is now available from Lonza Biologics entitled ‘A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs‘. Download the whitepaper to learn more about: Comprehensive CMC Solutions: Explore integrated Chemistry, Manufacturing, and Controls (CMC) strategies tailored to the unique challenges of Fab and… Read More
Download the whitepaper to learn more about: Comprehensive CMC Solutions: Explore integrated Chemistry, Manufacturing, and Controls (CMC) strategies tailored to the unique challenges of Fab and Fc-Fusion protein development. Overcoming Complexity: Learn how flexible approaches can streamline the development of complex protein formats, ensuring robust and scalable manufacturing processes. Accelerating Development… Read More
TargED Biopharmaceuticals, a biotechnology company focused on developing improved treatments for thrombotic diseases, has dosed the first participant with TGD001. TGD001 is a thrombolytic designed to break down clots of all sizes and compositions – from large clots which cause AIS, down to ‘micro-clots’ which cause conditions such as the… Read More
A new whitepaper is now available from Lonza Biologics entitled ‘A comprehensive and flexible approach to CMC for Fab and Fc-fusion development programs’. Read the whitepaper to: Gain insights into the diverse and complex structures of new molecular formats, often encompassing multiple chains and multiple domains Understand… Read More
Read this whitepaper to: Gain insights into the diverse and complex structures of new molecular formats, often encompassing multiple chains and multiple domains Understand the unique challenges faced during the process development and manufacture of these advanced proteins Explore how characterising these products and developing robust manufacturing processes can help… Read More
This whitepaper includes an introduction to antibodies and the process of antibody engineering based on Absolute Antibody’s years of experience developing recombinant versions of antibodies for a range of clients. This whitepaper will be valuable to: Therapeutic antibody developers Researchers designing antibodies for diagnostics Researchers looking to refine assays,… Read More
Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents. There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies. Compared to monoclonal antibodies produced using traditional hybridoma techniques,… Read More
